指南与共识消化、代谢与肾脏急症

第390号指南——子宫内膜增生的分类与管理

Guideline No. 390-Classification and Management of Endometrial Hyperplasia.
指南 / 共识 · J Obstet Gynaecol Can · 2019-01-01
一句话结论加拿大妇科肿瘤学会与妇产科学会指南推荐所有医疗提供者采用2014年世界卫生组织分类对子宫内膜增生进行分类,并据此指导药物或手术治疗。

本指南由加拿大妇科肿瘤学会与妇产科学会制定,目标人群为18岁及以上疑似或确诊子宫内膜增生的成年女性,适用者包括急诊医学专科在内的多学科医疗提供者。指南采用GRADE方法对证据质量与推荐强度进行分级,检索PubMed、Cochrane Wiley及Cochrane系统评价数据库,检索限于2000年后发表的英文人类研究,共识别2152项研究,纳入82项。指南旨在帮助初级保健医师和妇科医师对疑似子宫内膜增生进行初始评估,推荐统一使用2014年世界卫生组织分类,并指导确诊患者的最优治疗选择(药物或手术)。

要点

  • 推荐所有医疗提供者使用2014年世界卫生组织分类对子宫内膜增生进行分类(指南推荐)。
  • 指南适用于18岁及以上疑似或确诊子宫内膜增生的成年女性。
  • 适用用户包括急诊医学专科医师、妇科医师、产科医师、家庭医师、普通外科医师、护士及医学学员等。
  • 治疗选择涉及药物治疗与手术治疗,讨论涵盖伴或不伴非典型子宫内膜增生的女性。
  • 证据质量与推荐强度采用GRADE框架分级,共纳入82项研究。

适用人群与场景

  • 18岁及以上疑似或确诊子宫内膜增生的成年女性。
  • 适用场景包括初级保健与妇科初始评估,急诊医学专科医师亦为指南目标用户。

诊断标准与关键阈值

  • 推荐所有医疗提供者采用2014年世界卫生组织分类对子宫内膜增生进行分类(指南推荐)。

处置流程与药物剂量

  • 治疗选择包括药物治疗与手术治疗,讨论涵盖伴或不伴非典型子宫内膜增生的女性。

研究设计与关键结果

  • 指南由加拿大妇科肿瘤学会执行委员会与董事会审阅内容并提交意见,由加拿大妇产科学会董事会批准最终稿发表。
  • 证据检索于2018年4月进行,检索词包括子宫内膜增生、子宫内膜上皮内瘤变、子宫内膜取样、子宫内膜刮除、诊断,联合治疗、孕激素治疗、手术、左炔诺孕酮宫内释放系统(LNG-IUS)、芳香化酶抑制剂、二甲双胍,以及肥胖。
  • 共识别2152项研究,纳入82项研究进行综述。
  • 证据质量采用GRADE方法框架分级,并包含强推荐与弱推荐的解释。

证据类型、等级与局限

  • 证据类型:指南,采用GRADE方法框架对证据质量与推荐强度进行分级。
  • 证据检索限于2000年后发表的英文人类研究,检索于2018年4月进行。
  • 证据纳入顺序为:Meta分析、系统评价、指南、随机对照试验、前瞻性队列研究、观察性研究、非系统综述、病例系列及报告。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 指南旨在帮助初级保健医师和妇科医师对疑似子宫内膜增生女性进行初始评估。
  • 指南推荐统一使用2014年世界卫生组织分类,以指导确诊患者的治疗选择。
  • 指南预期有助于在药物和手术治疗前指导患者知情同意。
  • 证据将在发表5年后重新审查以决定是否更新全部或部分指南;若5年周期前有重要新证据发表,审查过程可能加速以更快更新部分推荐。

指南或共识出处

  • 指南名称:第390号指南——子宫内膜增生的分类与管理(Guideline No. 390-Classification and Management of Endometrial Hyperplasia)。
  • 发布机构:加拿大妇科肿瘤学会(Society of Gynecologic Oncology of Canada)与加拿大妇产科学会(Society of Obstetricians and Gynaecologists of Canada)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: The aim of this guideline is to aid primary care physicians and gynaecologists in the initial evaluation of women with suspected endometrial hyperplasia, to recommend the use of the 2014 World Health Organization classification for endometrial hyperplasia by all health care providers, and to guide the optimal treatment of women diagnosed with endometrial hyperplasia.

INTENDED USERS: Physicians, including gynaecologists, obstetricians, family physicians, general surgeons, emergency medicine specialists; nurses, including registered nurses and nurse practitioners; medical trainees, including medical students, residents, and fellows; and all other health care providers.

TARGET POPULATION: Adult women (18 years and older) presenting with suspected or confirmed endometrial hyperplasia.

OPTIONS: The discussion relates to the medical therapy as well as surgical treatment options for women with and without atypical endometrial hyperplasia.

EVIDENCE: For this guideline, relevant studies were searched in PubMed, Cochrane Wiley, and the Cochrane Systematic Reviews using the following terms, either alone or in combination, with the search limited to English language materials, human subjects, and published since 2000: (endometrial hyperplasia, endometrial intraepithelial neoplasia, endometrial sampling, endometrial curettage, diagnosis) AND (treatment, progestin therapy, surgery, LNG-IUS, aromatase inhibitors, metformin ), AND (obesity). The search was performed in April 2018. Relevant evidence was selected for inclusion in the following order: meta-analyses, systematic reviews, guidelines, randomized controlled trials, prospective cohort studies, observational studies, non-systematic reviews, case series, and reports. Additional significant articles were identified through cross-referencing the identified reviews. The total number of studies identified was 2152, and 82 studies were included in this review.

VALIDATION METHODS: The content and recommendations were drafted and agreed upon by the authors. The Executive and Board of the Society of Gynecologic Oncology of Canada reviewed the content and submitted comments for consideration, and the Board of the Society of Obstetricians and Gynaecologists of Canada approved the final draft for publication. The quality of evidence was rated using the criteria described in the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology framework. The interpretation of strong and weak recommendations was also included. The Summary of Findings is available upon request.

BENEFITS, HARMS, AND/OR COSTS: It is expected that this guideline will benefit women with endometrial hyperplasia. This should guide patient informed consent before both medical and surgical management of this condition.

GUIDELINE UPDATE: Evidence will be reviewed 5 years after publication to decide whether all or part of the guideline should be updated. However, if important new evidence is published prior to the 5-year cycle, the review process may be accelerated for a more rapid update of some recommendations.

SUMMARY STATEMENTS: RECOMMENDATIONS.

来源:J Obstet Gynaecol Can,查看原文。版权归原作者所有。

参考来源

  1. Auclair MH, Yong PJ, Salvador S, et al. Guideline No. 390-Classification and Management of Endometrial Hyperplasia. J Obstet Gynaecol Can. 2019. PMID: 31785798. doi:10.1016/j.jogc.2019.03.025

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。